EP Patent

EP2705839A1 — Pharmaceutical composition comprising lacidipine and process of preparation

Assigned to RIVOPHARM SA · Expires 2014-03-12 · 12y expired

What this patent protects

The invention relates to a solid pharmaceutical composition comprising lacidipine and polyvinylpyrrolidone, wherein the weight ratio of lacidipine to polyvinylpyrrolidone is about 10/90. The invention also relates to a process for preparing said composition comprises the step of:…

USPTO Abstract

The invention relates to a solid pharmaceutical composition comprising lacidipine and polyvinylpyrrolidone, wherein the weight ratio of lacidipine to polyvinylpyrrolidone is about 10/90. The invention also relates to a process for preparing said composition comprises the step of: a) providing a solution of polyvinylpyrrolidone and lacidipine in a polar solvent, b) spraying the solution of step a) onto a solid diluent, so as to obtain granules, c) optionally, adding to the granules obtained in step b) at least one additional excipient preferably selected from a glidant, a lubricant, a diluent and combinations thereof, and d) shaping the resulting granules into a solid form, preferably into a tablet.

Drugs covered by this patent

Patent Metadata

Patent number
EP2705839A1
Jurisdiction
EP
Classification
—
Expires
2014-03-12
Drug substance claim
No
Drug product claim
No
Assignee
RIVOPHARM SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.